AMLX Q3 2023 Earnings — Amylyx Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

AMLXAmylyx Pharmaceuticals, Inc.

$1B

Q3 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$103M+29666.1% YoY

Gross Profit

$97M94.9% margin

Operating Income

$19M18.2% margin

Net Income

$21M20.3% margin

EPS (Diluted)

$0.30

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$6M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$467M

Total Liabilities

$48M

Stockholders' Equity

$418M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$103M	$345,000	+29666.1%
Gross Profit	$97M	$173,000	+56243.9%
Operating Income	$19M	-$55M	+134.2%
Net Income	$21M	-$54M	+138.9%